Arcturus Therapeutics Holdings (ARCT) Receivables (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Receivables data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Receivables fell 90.78% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 90.78% YoY) and the FY2025 annual result came in at $9.2 million, up 41.62% from the prior year.
• Receivables retreated to $1.3 million in Q1 2026, from $9.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $92.5 million in Q1 2023 to a low of $1.3 million in Q1 2026.
• A 5-year average of $18.5 million and a median of $9.2 million in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables jumped 2405.64% — and 2026, when it sank 90.78%.
• Tracing ARCT's Receivables over 5 years: stood at $2.8 million in 2022, then surged by 1060.06% to $32.1 million in 2023, then plunged by 79.8% to $6.5 million in 2024, then surged by 41.62% to $9.2 million in 2025, then slumped by 85.36% to $1.3 million in 2026.
• The last three Receivables figures came in at $1.3 million (Q1 2026), $9.2 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.